Applications are invited for a post-doctoral fellowship from researchers with appropriate training and publication-documented expertise.
The successful applicant will join a project focused on understanding the molecular mechanism behind function of poorly understood tumor suppressor CSMD1. CSMD1 is a transmembrane protein and a complement inhibitor but also acts at tumor suppressor in several types of cancer including breast cancer. We have identified several potential mechanisms by which CSMD1 is exerting its action including interactions with other receptors crucial for cancer development and these will be now studied in depth.
The project will provide an opportunity to learn a broad range of advanced methods and to participate in collaborations with academic and clinical partners. The applicant will join the ongoing project in the multi-national research group of prof Anna Blom, who focuses on the innate immunity in physiology and pathology including cancer. We offer challenging project, which involves state-of-the-art instrumentation, and great educational opportunities in a dynamic research group with high reputation and collegial work culture.
Qualifications: Applicants should be highly motivated, independent, inventive and communicative with good English skills and with a PhD in cancer research, biochemistry, molecular biology or related discipline. Particularly valuable experience in cancer research, cell biology, protein expression and analysis, flow cytometry, microscopy, statistical analysis.
Applicants must have completed their PhD by the start of the appointment and within the last 3 years.
Applicants should submit by e-mail (email@example.com) curriculum vitae including publication list and e-mail address of two references at latest June 15th 2019. Starting date is flexible. The position is funded for 2 years in the first instance and may, subject to satisfactory performance and availability of funds, be extended. Tax-free stipend 2000 euro/month.
The group’s homepage:
Lund University is ranked within the top 100 of the world’s best universities. Our laboratory is placed in the middle of the university hospital in Malmö only 100 m from the train station with direct connection to Copenhagen airport (25 min). Please notice that the knowledge of Swedish is not necessary as the majority of Swedes can communicate in English.
Selected recent publications from the group relevant to the subject
Escudero-Esparza A., Kalchishkova N., Kurbasic E., Jiang W. G. and Blom A. M. (2013) The novel complement inhibitor human CUB and Sushi multiple domains (CSMD1) protein promotes Factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly., FASEB J., 27, 5083-93.
Escudero-Esparza A., Bartoschek M., Gialeli C., Okroj M., Owen S., Jirström K., Orimo A., Jiang W.G., Pietras K. and Blom A.M. (2016) Complement inhibitor CSMD1 acts as tumour suppressor in human breast cancer., Oncotarget, 7, 76920-76933
Englund E., Bartoschek M., Reitsma B., Jacobsson L., Escudero-Esparza A., Orimo A., Leandersson K., Hagerling C., Aspberg A., Storm P., Okroj M., Mulder H., Jirström K., Pietras K., and Blom A.M. (2016) Cartilage Oligomeric Matrix Protein (COMP) contributes to the development and metastasis of breast cancer., Oncogene, 35, 5585-5596.
Papadakos K.S., Bartoschek M., Rodriguez C., Gialeli C., Jin S., Lendahl U., Pietras K., and Blom A.M. (2019) Cartilage Oligomeric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling., Matrix Biology, in press.